Sadaf Durrani, Jasmin Shah, Mudassir Ahmad Khan, Muhammad Rasul Jan


OBJECTIVE: to study the relationship of adiponectin level with lipid
profile and glycemic control in type 2 diabetic subjects with and without
coronary heart disease (CHD).
METHODOLOGY: This cross-sectional/ analytical study consisted of
three groups. Group A consisted of 60 healthy subjects, group B consisted of 60 type 2 diabetic subjects and group C consisted of 60 type
2 diabetic subjects with coronary heart disease. The study participants
were analyzed for serum adiponectin level, triglycerides (TG), total
cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low
density lipoprotein cholesterol (LDL-C), very low density lipoprotein
cholesterol (VLDL-C), fasting blood glucose (FBG) and glycosylated
hemoglobin (HbA1c).
RESULTS: Significantly high adiponectin level was observed in female
subjects as compared to male subjects. Type 2 diabetic subjects with
and without coronary heart disease presented with significantly higher
FBG, HbA1c, TC and TG (p value <0.05) and significantly lower levels
of serum adiponectin and HDL-C (p value <0.001). Adiponectin level
showed significant positive association with HDL-C in control group
(female: r 0.988; p=<0.01, male: r 0.948; p=<0.01), type 2 diabetic
group (female: r 0.908; p=<0.01, male: r 0.860; p=<0.01) and type 2
diabetic group having coronary heart disease (female: 0.775; p=<0.01,
male: 0.650; p=<0.01). Significant (p value <0.01) negative association
of adiponectin was observed with TG, FBG and HbA1c in type 2 diabetic
subjects with and without coronary heart disease.
CONCLUSION: Hypoadiponectinemia in type 2 diabetic subjects with
and without coronary heart disease is related with un-controlled glycemic
status and dyslipidemia.

Full Text:




Anietabasi SO, Chinyere AO, Anousta

CN, Edmund RE, John UE, Anthony JU.

Adiponectin and cardiovascular risk factors

in relation with glycemic control in

type 2 diabetics. Int J Res Med Sci 2013;

(4): 563-70.

Mahler RJ, Adler ML. Type 2 diabetes mellitus:

Update on diagnosis, pathophysiology,

and treatment. J Clin Endocrinol Metab

; 84(4): 1165-71.

Efimov A, Sokolova L, Sokolov M. Diabetes

and coronary heart disease. Diabetol

Croat 2001; 30(4): 115-20.

Wild S, Roglic G, Green A, Sicree R, King

H. Global prevalence of diabetes. Estimates

for the year 2000 and projections

for 2030. Diabetes Care 2004; 27(5):


Robinson K, Prins J, Venkatesh B. Clinical

review: Adiponectin biology and its role in

inflammation and critical illness. Crit Care

; 15(2): 221-9.

Wells JC. Sexual dimorphism of body

composition. Best Pract Res Clin 2007;

: 415-30.

Ibrahim MM. Subcutaneous and visceral

adipose tissue: structural and functional

differences. Obes Rev 2010; 11: 11-8.

Ramirez ML, Garcia MAM, Nieto RM, Duran

EF, Insenser M, Alpanes M et al. Sexual

dimorphism in adipose tissue function as

evidenced by circulating adipokine secretions

in the fasting state and after an oral

glucose challenge. Human Reproduction

; 28(7): 1908-18.

Tsao TS1, Tomas E, Murrey HE, Hug C,

Lee DH, Ruderman NB, Heuser JE, Lodish

HF Role of disulfide bonds in Acrp30/

adiponectin structure and signaling specificity.

Different oligomers activate different

signal transduction pathways. J Biol Chem

Dec 12;278(50):50810-7.

Kadowaki T, Yamuchi T. Adiponectin and

adiponectin receptors. Endocr Rev 2005;

(3): 439-51.

Takemura Y, Walsh K, Ouchi N. Adiponectin

and cardiovascular inflammatory

responses. Curr Atheroscler Rep 2007;

(3): 238-43.

Geloneze B, Pereira JA, Pareja JC, Lima

MM, Lazarin MA, Souza IC, et al. Overcoming

metabolic syndrome in severe

obesity: Adiponectin as a marker of insulin

sensitivity and HDLcholesterol improvements

after gastric bypass. Arq Bras

Endocrinol Metabol 2009; 53: 293300.

Maruyama C, Ishibashi R, Araki R, Koike S,

Hirose H, Maruyama T. HMW adiponectin

associates with triglyceride concentrations

in type 1 diabetic patients. J Atheroscler

Thromb 2009; 16: 20716.

Friedwald WT, Levy PI, Fredrickson DS.

Estimation of concentration of low density

lipoprotein cholesterol in plasma, without

use of the preparative centrifuge. Clin

Chem 1972; 18(6): 449-502.

Delong DM, Delong ER, Wood PD, Lippet

K, Rifkind BM. A comparison of methods

for the estimation of plasma low and very

low density lipoprotein cholesterol. J Am

Med Assoc 1986; 256(17): 2372-7.

Lincoff AM, Wolski K, Nicholls SJ, Nissen

SE. Pioglitazone and risk of cardiovascular

events in patients with type 2 diabetes

mellitus: a meta-analysis of randomized

trials. J Am Med Assoc 2007; 298: 1180-8.

Tomas E, Tsao TS, Saha AK, Murrey HE,

Zhang Cc, Itani Si, Lodish HF, Ruderman

NB. Enhanced muscle fat oxidation and

glucose transport by Acrp30 globular

domain: acetyl CoA carboxylase inhibition

and AMP-activated protein kinase

activation. Proc Nat Acad Sci USA 2002;

(25): 16309-13.

Hopkins TA, Ouchi N, Shibata R, Walsh K.

Adiponectin actions in the cardiovascular

system. Cardiovasc Res 2007; 74(1): 11-8.

Bansal S, Buring JE, Rifai N, Mora S, Sacks

FM, Ridker PM. Fasting compared with

non-fasting triglycerides and risk of cardiovascular

events in women. J Am Med

Assoc 2007; 298(3): 299-308.

Lewis GF, Rader DJ. New insights into

the regulation of HDL metabolism and

reverse cholesterol transport. Circ Res

; 96(12): 1221-32.

Plant S, Shand B, Elder P, Scott R. Adiponectin

attenuates endothelial dysfunction

induced by oxidised low-density

lipoproteins. Diab Vasc Dis Res 2008;

(2): 120-8.

Cote M, Mauriege P, Bergeron J, Almeras

N, Tremblay A, Lemieux I, et al. Adiponectin

in visceral obesity: impact on glucose

tolerance and plasma lipoprotein and lipid

levels in men. J Clin Endocrinol Metab

; 90:14349.

Qiao I, Zou C, Van Der Westhuyzen

DR, Shao J. Adiponectin reduces plasma

triglyceride by increasing VLDL triglyceride

catabolism. Diabetes 2008; 57(7):


Nayak SB, Maharaj N, Fatt LaL. Association

between altered lipid profile, body

mass index, low plasma adiponectin and

varied blood pressure in Trinidad type 2

diabetic and non-diabetic subjects. J Med

Sci 2012; 65(9): 214-21.

Yamamoto S, Matsushita Y, Nakagawa T,

Hayashi T, Noda M, Mizoue T. Circulating

adiponectin levels and risk of type 2

diabetes in the Japanese. Nutr Diabetes.

Aug; 4(8): e130. doi: 10.1038/


Matsushita Y, Nakagawa T, Yamamota S,

Kato T, Ouchi T et al. Adiponectin and

visceral fat associate with cardiovascular

risk factors. Obesity 2014; 21: 287-91.

Saely CH, Riseh L, Hoefle G, Rein P,

Muendlein A, Marte T, et al. Low serum

adiponectin is independently associated

with both the metabolic syndrome and

angiographically determined coronary

atherosclerosis. Clin Chim Acta 2007(1-2);

: 97-102.

Luo M, Oza-Frank R, Narayan KMV,

Gokulakrishnan K, Mohan V. Serum total

adiponectin is associated with impaired

glucose tolerance in Asian Indian females

but not in males. J Diab Sci Tech 2010;

(3): 645-50.

Rasul S, Iihan A, M. H. Reiter, Baumgartner-

Parzer S, Kautzky-willer A. Relations

of adiponectin to levels of metabolic parameters

and sexual hormones in elderly

type 2 diabetic patients. Gender Medicine

; 8(2): 93-102.

Katsiki N, Mikhailidis DP, Gotzamani-

Psarrakou A, Didangelos TP, Yovos

JG, Karamitsos DT. Effects of improving

glycemic control with insulin on leptin,

adiponectin, ghrelin and neuropeptide

Y levels in patients with type 2 diabetes

mellitus: a pilot study. Open Cardiovasc

Med J 2011; 5(6): 136-47.

Kawamoto R, Tabara Y, Kohara K, Miki T,

Kusunoki T, Takayama S, Abe M, Katoh T,

Ohtsuka N. Relationships between lipid

profiles and metabolic syndrome, insulin

resistance and serum high molecular adiponectin

in Japanese community-dwelling

adults. Lipids Health Dis 2011; 10(79): 1-7.

Tabak AG, Brunner EJ, Miller MA, Karanam

S, McTernan PG, Cappuccino FP, et al. Low

serum adiponectin predicts 10-year risk of

type 2 diabetes and HbA1c independently

of obesity, lipids and inflammation-Whitehall

II study. Horm Met Res 2009; 41(8):


Snijder MB, Heine RJ, Seidell JC, Bouter

LM, Stehouwer CDA, Nijpels G, et al.

Associations of adiponectin levels with

incident impaired glucose metabolism and

type 2 diabetes in older men and women.

Diabetes Care 2006; 29(11): 2498-503.

Eynatten MV, Hamann A, Twardella D,

Nawroth PP, Brenner H, Rothenbacher D.

Relationship of adiponectin with markers

of systemic inflammation, atherogenic

dyslipidemia, and heart failure in patients

with coronary heart disease. Clin Chem

; 52(5): 853-9.

Kistorp C, Faber J, Galatius S, Gustafssen

F, Frystyk J, Flyvberg A, et al. Plasma adiponectin,

body mass index, and mortality

in patients with chronic heart failure. Circulation

; 112: 1756-62.

Laughlin GA, Barrett-Connor E, May S,

Langenberg C. Association of adiponectin

with coronary heart disease and mortality:

the Rancho Bernado study. Am J Epidemiol

; 165: 164-74.





linkedin: http://www.linkedin.com/profile/view?id=272237466&alinkedinuthType=NAME_SEARCH&authToken=XZ6J&locale=en_US&srchid=2722374661383810481309&srchindex=3&srchtotal=37&trk=vsrp_people_res_name&trkInfo=VSRPsearchId%3A2722374661383810481309%2CVSRPtargetId%3A272237466%2CVSRPcmpt%3Aprimary

Member of COPE http://publicationethics.org/members/kmuj-khyber-medical-university-journal-0

Work published in KMUJ is licensed under a  Creative Commons Attribution-NonCommercial 2.0 Generic License.

Creative Commons License